IL6 and systemic inflammatory response syndrome: Tocilizumab is an IL-6 inhibitor approved for rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome during CAR-T.(25,26) Preliminary data have shown that tocilizumab and other IL-6 blockers may have a role in severe SIRS cases, but its role in COVID-19 patients has not yet been confirmed, and its use should be considered experimetal.(27,28) Given its mode of action, it is plausible that tocilizumab is active in patients with already established SIRS (that could worsen), as opposed to the early use during the infection cycle with no demonstrable inflammatory activity.